India’s indigenous Covid-19 vaccine ‘Covaxin’ has been found to be 77.8 percent effective in the review of the Expert Committee of the Drug Controller General of India (DCGI). Hyderabad-based pharmaceutical company Bharat Biotech has recently handed over the Phase III trial of Made in India Covid-19 vaccine to DCGI.
At present, the three vaccines in India that people have been allowed to apply in the war against coronavirus in the country include indigenously developed covaccine.
In April this year, Bharat Biotech said that Covaxin has been found to be 78 per cent effective in mild and severe COVID-19 cases, based on its Phase III interim analysis. The Hyderabad-based pharmaceutical company had faced heavy criticism due to the delay in releasing data for the third phase of the vaccine trial.
DCGI had given permission for emergency use of Covaxin in India in the month of January on the basis of Phase I and Phase II trial data. Amidst the delay in releasing the data of the vaccine, it was claimed in the initial study that the Covishield vaccine produces more antibodies in the war against corona than Bharat Biotech’s Covaxin.
It was seen in the study that after 2 doses of the Covid-19 vaccine, the same antibodies were found in 98 percent of those who took Serum Institute of India’s Covishield, the same amount was found in 80 percent of those who applied Covaxin.
The World Health Organization (WHO) has also accepted Bharat Biotech’s Expression of Interest (EoI) for the covid-19 vaccine. In the WHO meeting on Wednesday, the data of the Phase III trial of the coronavirus vaccine will be reviewed. In this meeting, a decision can be taken to include Covaxin in the list of WHO for emergency use. If the WHO includes Covaxin in its list, then such people will be able to go abroad, who have taken the dose of Covaxin.
Earlier on June 12, the company said that the first and second phase trials of Covaxin vaccine were published in the famous journal ‘The Lancet‘. Bharat Biotech said, “At present, data from the Phase III trial on the efficacy and safety of Covaxin is being analyzed and compiled. Along with this, it has been ensured that its purity is not compromised. The company will soon make public the data of Phase III trials.